Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40-75
SponsorWake Forest University Health Sciences
About this trial
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
Eligibility criteria
Qualifiers
Evaluation for Acute Coronary Syndrome
Age 40-75 Years
10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or
Myocardial Infarction
Disqualifiers
ST-Segment Elevation Myocardial Infarction (STEMI) Activation
ST Depression >1 mm in Contiguous Leads
On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
Inability to Return for 30-day Follow-up
Trial design
Treatments tested in this trial
- Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
- Healthy Lifestyle Counseling
- Outpatient Followup
Treatment groups
130 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator
Source ClinicalTrials.gov